🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
16.69
+0.07 (0.42%)
Nov 20, 2026, 10:01 AM EST - Market open

Xeris Biopharma Holdings Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-6.50.55-54.84-62.26-94.66-122.73
Depreciation & Amortization
12.8412.6912.6313.1612.671.88
Other Amortization
3.573.373.012.211.560.96
Loss (Gain) From Sale of Assets
----0.24-
Loss (Gain) From Sale of Investments
---0.75-1.260.180.41
Stock-Based Compensation
31.2822.3718.3610.7212.1611.38
Other Operating Activities
30.78--6.57-3.290.110.7
Change in Accounts Receivable
-14.85-10.64-1.22-8.37-13.37-6.24
Change in Inventory
-9.96-19.29-8.78-14.8-7.47-7.42
Change in Accounts Payable
1.66-0.07-9.616.96-4.325.53
Change in Other Net Operating Assets
24.8219.6310.799.92-9.9919.98
Operating Cash Flow
73.6528.63-36.98-47.02-102.89-95.54
Operating Cash Flow Growth
597.54%-----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1.03-0.7-0.87-2.26-0.52-1.09
Cash Acquisitions
-----38.47
Investment in Securities
--5.75-3.7434.9960.58
Investing Cash Flow
-1.03-0.74.88-634.4697.96

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--50-146.21-
Long-Term Debt Repaid
-----43.5-
Net Debt Issued (Repaid)
-23.07-50-102.72-
Issuance of Common Stock
12.2622.271.730.5830.8427.84
Repurchase of Common Stock
-19.5-10.88-3.73-1.01-0.47-0.53
Other Financing Activities
-2.83--11.83-1.19-5.61-0.05
Financing Cash Flow
-33.1411.3936.17-1.61127.4727.25

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
------0
Net Cash Flow
39.4839.324.07-54.6459.0429.67

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
72.6227.93-37.85-49.29-103.42-96.62
Free Cash Flow Growth
628.02%-----
Free Cash Flow Margin
19.72%9.57%-18.64%-30.07%-93.80%-194.84%
Free Cash Flow Per Share
0.420.16-0.26-0.36-0.76-1.22
Levered Free Cash Flow
51.1125.97-31.62-19.62-65.85-28.19
Unlevered Free Cash Flow
64.6940.77-15.57-5.2-58.6-24.67

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
24.4627.1226.9527.6910.867.29
Change in Working Capital
1.68-10.36-8.82-6.29-35.1511.85
SEC Filings: 10-K · 10-Q